Superbugs are outsmarting antibiotics
Magellan Asset Management
In 1938, Ernst Chain, a German-born biochemist working at Oxford University, found an article on penicillin written nine years earlier by UK bacteriologist Alexander Fleming. In 1928, by fluke, Fleming noticed a zone around an invading fungus on an agar plate in which the bacteria did not grow. After isolating the mould, Fleming identified it as belonging to the Penicillium genus.
But doing anything more with the unstable compound was beyond Fleming's skills, which is where Chain stepped in. He proposed to his supervisor, Australian pathologist Howard Florey, that they isolate, purify and test the compound to see if it could kill microorganisms without harming their host. Florey, seeing penicillin's potential, assembled a team that in 1939 oversaw experiments where only treated mice survived.
By 1941, the group was experimenting on sick people. Because a UK stretched by war was incapable of producing enough penicillin, Florey travelled to the US to convince drug companies and officials to produce penicillin. When the US was drawn into World War II later that year, the government took over the mass production of penicillin to ensure the drug would be available for Allied forces. (It was by 1943).
In 1942, Fleming, who obtained some of the Oxford team's scarce penicillin, saved a UK woman who was dying of an infection. The Times of the UK published the feat, without referring to Fleming or Florey. Fleming's boss wrote to the newspaper praising Fleming who boasted in press interviews while Florey refused to speak to the media. Thus, many people today wrongly believe Fleming gifted penicillin to the world, even though Chain, Fleming and Florey equally shared the Nobel Prize for Physiology or Medicine 1945 and those in the know thought a self-promoter stole the credit from Florey.
What matters more is Florey's vision led to one of history's key medical feats. The drug's breakthrough advantage was how cheap it was to produce. The antibiotic became a worldwide cure and boosted life expectancy, mainly by reducing childhood deaths. By 1954, for instance, pneumonia's death toll on US toddlers had plunged 75% from 1939 levels.
Penicillin's wonders inspired the development of other affordable antibiotics that could combat an ever-wider array of ailments. As antibiotics, antifungals, antiviral and other drugs that are grouped as antimicrobials were developed, optimists dared talk of a world without deadly infections.
What could go wrong? Four things. First, in the advanced world where prescriptions are regulated, doctors overprescribed and misused antimicrobials. Second, in the unregulated emerging world, people can buy antibiotics (many counterfeit) at pharmacies without prescriptions and even find them at markets and shops. People thus mistreat or overtreat themselves with these medicines because it's cheaper and easier than seeing a doctor. The result is that up to 70% of human use may be inappropriate. Third, 80% of antibiotic use worldwide is to fatten farm livestock and prevent livestock infections. Efforts to curb such misuse have failed. The fourth problem is that antibiotic and antifungal residue is too prevalent in third-world drug-making hubs such as India's Hyderabad.
The result? The natural immunity microbes develop over time has accelerated. 'Superbugs' have built resistance to antimicrobials and global deaths from drug-resistant bugs are mounting. Before antibiotics, only about one in 10 million bacteria would prove resistant to antibiotics. Now, given that bacteria vulnerable to antibiotics can't survive, it is estimated that up to 90% of bacteria causing infections are immune to previously effective antibiotics.
As for deaths, a study led by researchers from the University of Washington out in January attributed 6.22 million deaths worldwide in 2019 to drug-resistant microbes (of which 1.27 million were a "direct result" of superbugs). A 2016 UK-government-commissioned study predicted that as "routine surgeries and minor infections will become life-threatening once again" deaths would reach 10 million annually by 2050 - by when the accumulated cost of superbugs would be US$100 trillion due to the need to use costlier treatments and longer hospital stays to save lives.
The University of Washington study suggested five ways to combat superbugs. First, improve sanitation and hygiene, especially for water, to limit infections. Second, prevent infections through vaccinations where possible. Third, reduce antimicrobial use in animals. Fourth, minimise the misuse of these drugs with people. Fifth, boost investment to find drugs that can defeat superbugs.
Here lies a key handicap in the battle against infections that fail to respond to treatment. Few superbug-busting drugs are appearing because investment in the field is minimal compared with other spheres of public health. Only about US$1 billion a year worldwide is spent on research to combat superbugs compared with US$50 billion a year tackling HIV/AIDS in low- and middle-income countries or an estimated US$157 billion to be spent on covid-19 vaccines through to 2025.
Pharmaceutical companies, which rely on prescription-based sales for revenue, aren't investing enough because they can't recoup an adequate return for three reasons. First, the cheapness of antimicrobial generics makes hospitals reluctant to pay high prices for superbug stoppers. Another problem is that medical facilities use new superbug-busters as a fallback when generic treatments fail. A third hitch is that antimicrobials are taken for a short time only, whereas profitable drugs are usually ones that people take daily for years. The outcome is that sales volumes are too small to make new drugs profitable. As a sign of how fragile are the economics in this sphere, Big Pharma players have abandoned the superbug fight and smaller antibiotic-development companies struggle to survive, even after gaining approval for their finds.
A crisis around superbugs is building. A market failure means capitalism can't yet derive a solution to diffuse a foreseeable catastrophe. Governments need to do more when it comes to funding research and offering financial incentives for private enterprise because only alarming levels of deaths will improve the economics. Even though the pharmaceutical industry is likely to solve the problem in extremis, it would be too late for millions of people.
To be fair, policymakers are trying to stop the misuse of antibiotics - but with little success in the emerging world. To be fair again, authorities have tried to help develop superbug-busters. The PASTEUR Act of 2021 before US Congress provides incentives for research. The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, which is a public-private initiative, is spending US$480 million from 2016 to 2022 to solve the problem. A UK initiative unveiled in April could become a global template for encouraging research because it offers to pay drug companies a fixed fee for supplying antibiotics. Success might come but moneywise these efforts don't compare with the billions Big Pharma spends on research in lucrative areas. Some superbugs arise out of nature so antibiotic misuse and overuse are not to blame for all of them. Doctors are finding novel ways to combat superbugs. Phage therapy, the use of specific viruses to target bacterial infections, is one of them.
But greater efforts are needed. Surely in the medtech age, someone can discover a cure for superbugs. No one will care if self-promoters pinch the credit.
A flawed model
Before 1870, US pharmacies were virtually unregulated. Chemists sold remedies without prescriptions, heavily promoted quack cures and sold drugs now illegal such as cocaine, heroin and opium. Doctors overprescribed doses to be obtained from pharmacies because they knew chemists watered down medication. Newspapers so relied on advertising by drug companies they downplayed medical mishaps. By 1906, the harm to society was prominent enough to warrant the passing of the Pure Food and Drug Act, the first step in the US to regulate drug marketing.
The act gave rise to the Food and Drug Administration, the US's oldest consumer-protection agency. Tougher laws in 1938 meant new drugs required the body's approval and some medicines required doctor prescriptions. This doctor oversight meant the big drug companies founded after World War II aimed their advertising at doctors, not the public - by 1961, about 60% of the advertising budgets of the 22 biggest drug firms was targeted at doctors. Thus formed the pharmaceutical business model, whereby drug companies identify promising molecules, test them, and, once gaining approval, target the medical industry for sales. Success is a 'blockbuster drug' that reaps annual sales topping US$1 billion year after year.
The model has provided the world with many wonder drugs but it's flawed at the same time. A major disadvantage is that many discoveries are so expensive as to be unaffordable. Another is a slowing rate of discovery of effective medicines - most of the breakthroughs such as antibiotics, the polio vaccine, heart treatments, chemotherapy and radiation for cancer were discovered between 1940 and 1980. In terms of antibiotics, no major advances have come since the 1980s - new drugs are variations rather than breakthroughs.
A third disadvantage with the pharmaceutical business model is that the economics of certain spheres of medical research are so poor Big Pharma avoids the area and specialist start-ups can't survive. Such is the fate of research against superbugs.
In 2018, Novartis joined Allergan of the US, AstraZeneca of UK-Swedish origins, GlaxoSmithKline of the UK, The Medicines Company of the US and France-based Sanofi in quitting the fight against infections.
One comfort when Big Pharma companies dodge the superbug fight is they often sell their infection-disease research units to small biotechs. The Medicines Company, for instance, in 2017 sold its portfolio to Melinta Therapeutics of the US, while AstraZeneca in 2018 hived off part of its antibiotic research to Entasis Therapeutics (which just announced a promising cure).
But Little Pharma is besieged. The World Health Organisation says the smaller and mid-sized companies that dominate the preclinical and clinical antibiotic pipeline are "struggling to find investors to finance late-stage clinical development up to regulatory approval". As such, many companies disappear and so do their finds. Of 15 new antibiotics approved in the US in the decade to 2020, five were shelved as companies applied for bankruptcy or were sold.
Take, for example, the experience of Achaogen. The US company collapsed in 2019 after spending about US$1 billion over 15 years to win Food and Drug Administration approval for Zemdri, a drug for hard-to-treat urinary tract infections and one the World Health Organization classes as an essential medicine.
Somehow Zemdri is still available. To overcome the overall market failure that prevents the discovery of similar feats, the OECD said in 2017 it would take an extra US$500 million per year over a decade to make available four new 'first-in-class' antibiotics. Governments need to make this happen, just like the US government, thanks to Florey's efforts, ensured enough penicillin for the military in World War II.
Funds operated by this manager:
Magellan Global Fund (Hedged), Magellan Global Fund (Open Class Units) ASX:MGOC, Magellan High Conviction Fund, Magellan Infrastructure Fund, Magellan Infrastructure Fund (Unhedged), MFG Core Infrastructure Fund
 Sir Ernst Boris Chain. British biochemist. Britannica biography. britannica.com/biography/Ernst-Boris-Chain
 Alexander Fleming. Scottish bacteriologist. Britannica biography. britannica.com/biography/Alexander-Fleming
 Robert Gaynes. 'The discovery of penicillin - new insights after more than 75 years of clinical use.' US National Library of Medicine. National Institute of Health. May 2017. ncbi.nlm.nih.gov/pmc/articles/PMC5403050/
 Howard Walter Florey, Baron Florey. Britannica biography. britannica.com/biography/Howard-Florey
 Norman George Heatley. Biography. The Lancet. Published 7 February 2004. thelancet.com/journals/lancet/article/PIIS0140-6736(04)15511-6/fulltext
 'The Nobel Prize for Physiology or Medicine 1945.' The Nobel Prize. The prize-awarding committee credited Chain, Fleming and Florey with 'Prize share: 1/3.' nobelprize.org/prizes/medicine/1945/summary/
 Robert Gordon. 'The rise and fall of American growth.' Princeton University Press. 2016. Page 465.
 By 2001, antibiotics had largely rid the US of tuberculosis; incidence of the disease that year was fewer than six cases per 100,000.
 Financial Times. 'Antibiotic resistance in Africa: 'a pandemic that is already here'. 7 March 2022. ft.com/content/95f150df-5ce6-43cf-aa8d-01ac3bdcf0ef
 Foreign Affairs. 'When antibiotics stop working.' 28 February 2022. foreignaffairs.com/articles/world/2022-02-28/when-antibiotics-stop-working
 Foreign Affairs. Op cit.
 See 'Antibiotic use in US farm animals was falling. Now it's not.' WIRED. 14 December 2021. wired.com/story/antibiotic-use-in-us-farm-animals-was-falling-now-its-not/
 Foreign Affairs. Op cit.
 The study found that one in five deaths were of children under five years old, while nearly 80% of deaths were attributed to three causes: blood, intra-abdominal and lower respiratory and thorax infections. 'Antimicrobial resistance collaborators' (pen name of authors). The Lancet. 'Global burden of bacterial antimicrobial resistance in 2019: a systemic analysis.' Volume 399, Issue 10325. Pages 629 to 655. The study calculated that 1.27 million deaths were the "direct result" of drug-resistant bacterial infections and 4.95 million deaths were "associated" with them, many of them in the emerging world. Published on the web 19 January 2022. thelancet.com/journals/lancet/article/PIIS0140-6736(21)02724-0/fulltext. Excerpt.
 Review on Antimicrobial Resistance. 'Tackling drug-resistant infections globally.' The review was commissioned in 2014 by then UK prime minister David Cameron. amr-review.org/. In 2019, the US Centers for Disease Control and Prevention warned that, as the US was recording 2.8 million drug-resistant infections a year, people should "stop referring to a coming post-antibiotic era - it's already here". Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States.' 2019. Page V. cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
 Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States.' 2019. Page V. cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf
 'Antimicrobial resistance collaborators'. Op cit. Pages 641 and 649.
 Foreign Affairs. Op cit.
 Reuters. 'World to spend $157 billion on covid-19 vaccines through 2025 - report.' 29 April 2021. reuters.com/business/healthcare-pharmaceuticals/world-spend-157-billion-covid-19-vaccines-through-2025-report-2021-04-29/
 US Congress. 'S.2076 - PASTEUR Act of 2021.' congress.gov/bill/117th-congress/senate-bill/2076
 Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator. 'Accelerating global antibacterial innovation.' carb-x.org/about/overview/
 'UK launches world-first 'subscription' model for antibiotic supply.' Financial Times. 12 April 2022. ft.com/content/c7cbebe4-8597-4340-8c55-56c4b423c1d1
 'Hedgehogs had MRSA superbug long before antibiotics use, research finds.' The Guardian. 7 January 2022. theguardian.com/science/2022/jan/06/hedgehogs-had-mrsa-superbug-long-before-antibiotics-use-research-finds
 'Phage therapy offers hope in fight against antibiotic resistance and superbugs.' Australian Broadcasting Corp. 15 January 2021. abc.net.au/news/2021-01-15/antibiotic-resistant-superbug-bacteriophage-therapy/12213010
 Gordon. Op cit. Pages 222 to 223.
 Food and Drug Administration. 'FDA history.' fda.gov/about-fda/fda-history
 Gordon. Op cit. Page 476.
 Gordon. Op cit. Page 594. Jan Vijg, a Netherlands-born molecular geneticist and author of 'The American Technological Challenge: Stagnation and decline in the 21st century', blamed society's risk aversion for the spluttering growth rate. Medical advances are impeded or abandoned if even a minute fraction of people in clinical trials have adverse reactions. See 'Did we hit our innovation peak in 1970?' The Wall Street Journal. 16 June 2014. wsj.com/articles/BL-REB-26133
 See World Health Organisation. '2020 antibacterial agents in clinical and preclinical development: an overview.' 15 April 2021. who.int/publications/i/item/9789240021303
 See Monthly Review. 'Superbugs in the Anthropocene.' 1 June 2019. monthlyreview.org/2019/06/01/superbugs-in-the-anthropocene/
 Bloomberg News. 'Superbugs win another round as Big Pharma leaves antibiotics.' 13 July 2018. bloomberg.com/news/articles/2018-07-13/superbugs-win-another-round-as-big-pharma-leaves-antibiotics. See also Financial Times. 'How pharma economics hold back antibiotic development.' 7 March 2022. ft.com/content/29292a3c-321d-4187-9ff0-59d70eb796f4
 Businesswire. 'The Medicines Company announces definitive agreement to sell its infectious disease business unit to Melinta Therapeutics.' 29 November 2017. businesswire.com/news/home/20171129005573/en/The-Medicines-Company-Announces-Definitive-Agreement-to-Sell-its-Infectious-Disease-Business-Unit-to-Melinta-Therapeutics
 Fierce Biotech publication. 'AstraZeneca spinout Entasis files for $86m IPO to fund antibiotic phase 3.' 20 August 2018. fiercebiotech.com/biotech/astrazeneca-spinout-entasis-files-for-86m-ipo-to-fund-antibiotic-phase-3
 Fierce Biotech publication. 'Entasis' antibiotic bests last resort treatment on path to become new weapon against drug-resistant bacteria.' 20 October 2021. fiercebiotech.com/biotech/entasis-zai-labs-antibiotic-sul-dur-beats-comparator-phase-3-trial
 Bloomberg News. 'The world's next big health emergency is already here.' 27 January 2022. bloomberg.com/opinion/articles/2022-01-27/after-covid-antimicrobial-resistance-is-the-world-s-biggest-health-emergency
 See 'Crisis looms in antibiotics as drug makers go bankrupt.' The New York Times. 25 December 2019. nytimes.com/2019/12/25/health/antibiotics-new-resistance.html
 For suggestions of what governments could do, see 'Tackling antimicrobial resistance ensuring sustainable R&D.' OECD. 29 June 2017. oecd.org/g20/summits/hamburg/Tackling-Antimicrobial-Resistance-Ensuring-Sustainable-RD.pdf
Important Information: This material has been delivered to you by Magellan Asset Management Limited ABN 31 120 593 946 AFS Licence No. 304 301 ('Magellan') and has been prepared for general information purposes only and must not be construed as investment advice or as an investment recommendation. This material does not take into account your investment objectives, financial situation or particular needs. This material does not constitute an offer or inducement to engage in an investment activity nor does it form part of any offer documentation, offer or invitation to purchase, sell or subscribe for interests in any type of investment product or service. You should read and consider any relevant offer documentation applicable to any investment product or service and consider obtaining professional investment advice tailored to your specific circumstances before making any investment decision. A copy of the relevant PDS relating to a Magellan financial product or service may be obtained by calling +61 2 9235 4888 or by visiting www.magellangroup.com.au.
Past performance is not necessarily indicative of future results and no person guarantees the future performance of any strategy, the amount or timing of any return from it, that asset allocations will be met, that it will be able to be implemented and its investment strategy or that its investment objectives will be achieved. This material may contain 'forward-looking statements'. Actual events or results or the actual performance of a Magellan financial product or service may differ materially from those reflected or contemplated in such forward-looking statements.
This material may include data, research and other information from third party sources. Magellan makes no guarantee that such information is accurate, complete or timely and does not provide any warranties regarding results obtained from its use. This information is subject to change at any time and no person has any responsibility to update any of the information provided in this material. Statements contained in this material that are not historical facts are based on current expectations, estimates, projections, opinions and beliefs of Magellan. Such statements involve known and unknown risks, uncertainties and other factors, and undue reliance should not be placed thereon.
Any trademarks, logos, and service marks contained herein may be the registered and unregistered trademarks of their respective owners. This material and the information contained within it may not be reproduced, or disclosed, in whole or in part, without the prior written consent of Magellan.